SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31

SELLAS Life Sciences Group, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$10.49+0.51 (+5.11%)

Close on Oct 19, 2026

Market cap: $1.98B
P/E (TTM): –
Dividend yield: –

SELLAS Life Sciences Group, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	–	–	0	1.00	7.60	1.90	0	–	–	–	–	9.32	2.49	0	0	–
Cost of Revenue	0	0	0	0.10	0.20	0	–	–	–	–	–	1.40	0.52	0	0	–
Gross Profit	–	–	0	0.90	7.40	1.90	–	–	–	–	–	7.92	1.97	0	0	–
Research & Development	16	19	24	20	16	9.28	7.29	8.77	6.07	11	24	28	20	15	3.85	7.87
Selling, General & Admin	12	12	14	13	11	9.60	9.92	13	15	4.59	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	–	–	–	6.59	8.64	8.75
Operating Expenses	–	–	–	–	–	–	–	–	–	32	34	44	28	21	12	17
Total Costs & Expenses	28	32	38	43	33	19	20	31	23	–	–	–	–	–	–	–
Operating Income	-28	-32	-38	-42	-25	-17	-20	–	-23	-16	-34	-44	-28	-21	-12	–
Other Non-Operating Income	1.41	0.63	0.53	0.65	4.36	0.21	-19	-29	-24	21	-4.37	16	-42	-13	9.08	4.63
Asset Impairment Charges	0	0	0	0	0	0	0	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	0	0	3.91	0	0	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	0	-4.55	0	0	0	-0.01	–
Legal Settlements	–	–	–	–	–	–	–	–	–	-2.75	-5.28	0	0	–	–	–
Pretax Income	-27	-31	-37	-41	-21	-17	-19	-29	-24	-18	-39	-28	-70	-34	-3.41	-12
Income Tax Expense	0	0	0	0	-0.24	-0.02	-0.08	-1.38	0.25	0.00	0.37	0	1.05	-1.05	–	–
Income from Continuing Operations	–	–	–	–	–	-17	-19	-28	-24	-11	-39	-28	-71	-33	-3.41	–
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	12	25	8.32	5.35	-1.64	-8.08	–
Net Income	-27	-31	-37	-41	-21	-17	-19	-28	-24	-18	-64	-37	-77	-35	-11	-12
Preferred Dividends	–	–	–	–	–	–	0	4.44	0	–	–	–	–	–	–	–
Net Income to Common	–	–	–	–	-21	-17	-28	-41	-24	-18	–	–	–	–	–	–
EPS (Basic)(per share)	-0.25	-0.50	-1.34	-2.13	-1.34	-2.11	-10.92	-157.72	-522.00	-933.00	-411.50	-306.50	-850.00	-560.00	-320.00	-670.00
EPS (Diluted)(per share)	-0.25	-0.50	-1.34	-2.13	-1.34	-2.11	-10.92	-157.72	-522.00	-933.00	-411.50	-306.50	-850.00	-560.00	-320.00	-670.00
Shares Outstanding (Basic, Weighted)(shares)	109	61	28	19	15	7.98	2.56	0.26	0.05	0.02	0.16	0.12	0.09	0.06	0.04	–
Shares Outstanding (Diluted, Weighted)(shares)	109	61	28	19	15	7.98	2.56	0.26	0.05	0.02	0.16	0.12	0.09	0.06	0.04	–
EBITDA	–	–	–	–	–	–	–	–	–	-16	-34	-44	-28	-21	-12	–
Net Interest Income	–	–	0.53	0.32	0.01	0.03	0.12	-0.27	-0.46	-1.17	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -66.9%

Financial strength

Current ratio: 18.83
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1827.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 14.42
Dividend yield: –